Skip to main content
SpringerLink
Log in

Le Mid regional proadrenomedullin (MRproADM)

  • Chapter
Les biomarqueurs en médecine d’urgence

Part of the book series: Références en médecine d’urgence. Collection de la SFMU ((REFERMED))

  • 649 Accesses

Résumé

L’adrénomédulline (ADM) est une hormone découverte au début des années 1990, qui connaît un regain d’intérêt dans le domaine d’application des biomarqueurs. Initialement caractérisée dans les glandes surrénales, l’ADM a été détectée dans de nombreux autres tissus et la circulation systémique. Son activité biologique dépend de sa forme mature. Les propriétés vasomotrices de l’ADM ont suggéré son intérêt potentiel comme témoin de l’équilibre hémodynamique. Récemment, les progrès techniques conduisant au dosage plus stable de la pro-hormone ont permis de mieux étudier et comprendre le rôle de l’ADM dans diverses situations cliniques aigués, et son intérêt comme marqueur de sévérité.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Becker KL, Nylen ES, White JC et al. (2004) Procalcitonin and the calcitonin gene family of peptides in inflammation, infection and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 89: 1512–1525

    Article  PubMed  CAS  Google Scholar 

  2. Morgenthaler NG, Struck J, Alonso C, Bergmann A (2005) Measurement of Midregional Proadrenomedullin in Plasma with an Immunoluminometric Assay. Clin Chem 51: 1823–1829

    Article  PubMed  CAS  Google Scholar 

  3. Kitamura K, Kangawa K, Kawamoto M, et al. (1993) Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192: 553–560

    Article  PubMed  CAS  Google Scholar 

  4. Samson WK (2001) Proadrenomedullin derived peptides. Front Neuroendocrinol 19: 100–127

    Article  Google Scholar 

  5. Yanagawa B, Nagaya N (2007) Adrenomedullin: molecular mechanisms and its role in cardiac disease. Amino Acids 32: 157–164

    Article  PubMed  CAS  Google Scholar 

  6. Matsui E, Kitamura K, Yoshida M, et al. (2001) Biosynthesis and secretion of adrenomedullin and pro-adrenomedullinN-terminal 20 peptide in a rat model of endotoxin shock. Hypertens Res 24: 543–549

    Article  PubMed  CAS  Google Scholar 

  7. Nishikimi T, Kitamura K, Saito Y, et al. (1994) Clinical studies on the sites of production and clearance of circulatingadrenomedullin in human subjects. Hypertension 24: 600–604

    Article  PubMed  CAS  Google Scholar 

  8. Vizzaa CD, Letiziab C, Sciomera S, et al. (2005) Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with end-stage pulmonary disease. Regul Peptide 124: 187–193

    Article  Google Scholar 

  9. Samson WK (2001) Proadrenomedullin derived peptides. Front Neuroendocrinol 19: 100–127

    Article  Google Scholar 

  10. Yanagawa B, Nagaya N (2007) Adrenomedullin: molecular mechanisms and its role in cardiac disease. Amino Acids 32: 157–164

    Article  PubMed  CAS  Google Scholar 

  11. Shimosawa T, Ito Y, Ando K, et al. (1995) Proadrenomedullin NH2-terminal 20 Peptide, a New Product of the Adrenomedullin Gene, Inhibits Norepinephrine Overflow from Nerve Endings. J Clin Invest 96: 1672–1676

    Article  PubMed  CAS  Google Scholar 

  12. Behnes M, Papassotiriou J, Walter T, et al. (2008) Long-term prognostic value of midregional pro-adrenomedullin and C-terminal pro-endothelin-l in patients with acute myocardial infarction. Clin Chem Lab Med 462: 204–211

    Article  Google Scholar 

  13. Khan SQ, O’Brien RJ, Struck J, et al. (2007) Prognostic Value of Midregional Pro-Adrenomedullin in Patients With Acute Myocardial Infarction. J Am Coll Cardiol 49: 1525–1532

    Article  PubMed  CAS  Google Scholar 

  14. Dhillon OS, Khan SQ, Narayan HK, et al. (2010) Prognostic Value of Mid-Regional Pro-Adrenomedullin Levels Taken on Admission and Discharge in Non—ST-Elevation Myocardial Infarction. The LAMP (Leicester Acute Myocardial Infarction Peptide) II Study. J Am Coll Cardiol 56: 125–133

    Article  PubMed  CAS  Google Scholar 

  15. Stolz D, Christ-Crain M, Morgenthaler NG, et al. (2008) Plasma proadrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest 134: 263–272

    Article  PubMed  CAS  Google Scholar 

  16. Struck J, Tao C, Morgenthaler NG, Bergmann A (2004) Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 25: 1369–1372

    Article  PubMed  CAS  Google Scholar 

  17. Christ-Crain M, Morgenthaler NG, Struck J, et al. (2005) Mid-regional proadrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 9:R816–824

    Article  PubMed  Google Scholar 

  18. Guignant C, Voirin N, Venet F, et al. (2009) Assessment of pro-vasopressin and pro-adrenomedullin as predictors of 28-day mortality in septic shock patients. Intensive Care Med 35: 1859–1867

    Article  PubMed  Google Scholar 

  19. Christ-Crain M, Morgenthaler NG, Stolz D, et al. (2006) Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 10: R96

    Article  PubMed  Google Scholar 

  20. Huang DT, Angus DC, Kellum JA, etal. (2009) Midregionalproadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 136: 823–831

    Article  PubMed  CAS  Google Scholar 

  21. Schuetz P, Wolbers M, Christ-Crain M, et al. ProHOSP Study Group (2010) Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care 14: R106

    Article  PubMed  Google Scholar 

  22. Krüger S, Ewig S, Giersdorf S, et al. (2010) the German Competence Network for the Study of Community Acquired Pneumonia (CAPNETZ) Study Group. Cardiovascular and Inflammatory Biomarkers to Predict Short-and Long-Term Survival in Community-acquired Pneumonia: Results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 182: 1426–1434

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. département de médecine d’urgence, Centre hospitalier Princesse Grace, 1 avenue Pasteur, BP 489, MC-98012, Monaco

    Y.-É. Claessens

  2. Service des urgences, Hôpital Cochin et Université Paris-Descartes, Faculté de médecine, 27, rue du Faubourg-Saint-Jacques, 75679, Paris Cedex 14, France

    É. Trabattoni

Authors
  1. Y.-É. Claessens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. É. Trabattoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Département de médecine d’urgence, Centre hospitalier Princesse Grace, 1, avenue Pasteur, BP 489, MC-98012, Monaco

    Yann-Érick Claessens

  2. Hôpital Tenon Service d’accueil des urgences, UPMC-Paris 6, 4, rue de la Chine, 75020, Paris, France

    Patrick Ray

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Claessens, YÉ., Trabattoni, É. (2012). Le Mid regional proadrenomedullin (MRproADM). In: Claessens, YÉ., Ray, P. (eds) Les biomarqueurs en médecine d’urgence. Références en médecine d’urgence. Collection de la SFMU. Springer, Paris. https://doi.org/10.1007/978-2-8178-0297-8_20

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0297-8_20

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0296-1

  • Online ISBN: 978-2-8178-0297-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation